An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Dec 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Enzalutamide (Primary) ; Rucaparib (Primary)
Indications Adenocarcinoma; Bladder cancer; Carcinoma; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms ATLANTIS

21 Sep 2022 Status changed from active, no longer recruiting to completed.
12 Aug 2022 Primary endpoint has not been met (Progression free survival- RECIST 1.1 tumour measurements, assessed 12 weekly during trial treatment. PFS is time from randomisation until progression or death, whichever occurs first) , according to Results published in the Journal of Clinical Oncology
12 Aug 2022 Results published in the Journal of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com